

REMARKS

Claims 1-3 and 7 are in the application. Claim 7 has been amended.

The Examiner has indicated that Claims 1-3 are allowed

The rejection of Claim 7 under 35 USC112, first paragraph has been maintained by the Examiner. It is the Examiner's position that Applicants' specification is not enabling for "Alzheimer's disease." Applicants have amended claim 7 to a method for treatment of cognitive impairment. Basis for the amendment to Claim 7 be found in the specification (page 9, paragraphs [0143]-[0144] where it is stated,


Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular cognitive impairments in diseases such as Alzheimer's disease and related neurodegenerative disorders.

Attached is a paper which links H₃ antagonism with cognitive impairment in Alzheimer's disease: A. Medhurst et al., "GSK 189254, a Novel H₃ Receptor Antagonist That Binds to Histamine H₃ Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models," *The Journal of Pharmacology and Experimental Therapeutics*, Volume 321: 1032-1045, 2007. It is also pointed out that in the introduction of Applicants' specification (page 1, paragraph [0003]) reference is made to a paper which indicates H₃ antagonists could be useful in the treatment of cognitive impairment; see, Giovanni et al., (1999), *Behav. Brain Res.* 104, 147-155.

Accordingly, it is respectfully requested this rejection of Claim 7 be reconsidered and withdrawn and that the application as amended be allowed.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: November 4, 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988